The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status
- 1 January 1994
- journal article
- Published by Springer Nature in Virchows Archiv
- Vol. 424 (1), 47-51
- https://doi.org/10.1007/bf00197392
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.1993
- p53, guardian of the genomeNature, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.Proceedings of the National Academy of Sciences, 1991
- Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.The Journal of Immunology, 1990
- Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cellsNature, 1988
- Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.Molecular and Cellular Biology, 1988
- Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.Proceedings of the National Academy of Sciences, 1985
- Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInternational Journal of Cancer, 1983